US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.
This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.
Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine."
"This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he added
Biden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May.
"This country will have enough vaccines supply for every adult in America by the end of May," Biden said on Tuesday.
The United States has reported more than 28.7 million confirmed Covid-19 cases and over 514,000 reported deaths. The demand for vaccines still far exceeds supply and these vaccines can't come soon enough.
The official emergency use authorization for Johnson & Johnson's (J & J) single-dose vaccine comes after an FDA advisory panel voted 22-0 to recommend authorization on Friday.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)